

REFERENCES

- Adler C, et al. Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging study. *Bipolar Disord.* 2004;6(3):197-203.
- Allebeck P. Schizophrenia: a life-shortening disease. *Schizophr Bull.* 1989;15(1):81-89.
- Allison D, et al. The distribution of body mass index among individuals with and without schizophrenia. *J Clin Psychiatry.* 1999;60(4):215-220.
- Altshuler L, et al. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: an MRI study demonstrating neuroanatomic specificity. *Arch Gen Psychiatry.* 1998;55(7):663-664.
- Angst F, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. *J Affect Disord.* 2002;68(2-3):167-181.
- Baldessarini R, et al. Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. *Psychiatr Serv.* 2007;58(1):85-91.
- Berk M, et al. Early intervention in bipolar disorders: opportunities and pitfalls. *Med J Aust.* 2007;187(S7):S11-S14.
- Berretta S, et al. Neuron numbers and volume of the amygdala in subjects diagnosed with bipolar disorder or schizophrenia. *Biol Psychiatry.* 2007;62(8):884-893.
- Biederman J, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. *Biol Psychiatry.* 2005;58(7):589-594.
- Blader J, Carlson G. Increased rates of bipolar disorder diagnoses among US child, adolescent, and adult inpatients, 1996-2004. *Biol Psychiatry.* 2007;62(2):107-114.
- Blumberg H, et al. A functional magnetic resonance imaging study of bipolar disorder. *Arch Gen Psychiatry.* 2003;60(6):601-609.
- Blumberg H, et al. Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. *Biol Psychiatry.* 2006;59:611-618.
- Buckley P, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. *Schizophr Res.* 2005;79:281-288.
- Caetano S, et al. Abnormal corpus callosum myelination in pediatric bipolar patients. *J Affect Disord.* 2008;108(3):297-301.
- Calabrese J, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. *Am J Psychiatry.* 2005;162:1351-1360.
- Calabrese J, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. *Bipolar Disord.* 2008;10:323-333.
- Calabrese J, et al. Treatments for bipolar depression: monotherapy or concomitant therapy. *Eur Neuropsychopharmacol.* 2007;17(S4):S355.
- Cassidy F, et al. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. *Am J Psychiatry.* 1999;156(9):1417-1420.
- Cecil K, et al. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. *Bipolar Disord.* 2002;4(6):357-365.
- Cecil K, et al. Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk of bipolar disorders. *J Child Adol Psychopharm.* 2003;13(4):545-555.
- Chang K, et al. Efficacy of aripiprazole in children (10-17 years old) with mania. Abstract presented at: 54th Annual AACAP Meeting; October, 2007; Boston, MA.
- Chang K, et al. Decreased N-acetylaspartate in children with familial bipolar disorder. *Biol Psychiatry.* 2003;53(11):1059-1065.
- Chang K, et al. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. *J Am Acad Child Adolesc Psychiatry.* 2006;45(3):298-304.

MEASURE^{me}TM

Modeling Effective Antipsychotic Therapeutic Success by Utilizing Real Evidence

Colton C, Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis*. 2006;3(2):1-14. Available at: http://www.cdc.gov/pcd/issues/2006/apr/05_0180.htm. Accessed March 2008.

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. *Diabetes Care*. 2004;27(2):596-601.

Correll C, et al. Safety and tolerability of aripiprazole in children (10-17 years old) with mania. Abstract presented at: 54th Annual AACAP Meeting; October, 2007; Boston, MA.

Dager S, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. *Arch Gen Psychiatry*. 2004;61(5):450-458.

Davidson S, et al. Cardiovascular risk factors for people with mental illness. *Aust N Z J Psychiatry*. 2001;35(2):196-202.

DelBello M, et al. Efficacy of quetiapine in children and adolescents with bipolar mania. Abstract presented at: 54th Annual AACAP Meeting; October, 2007; Boston, MA.

DelBello M, et al. Pharmacological treatment of youth with bipolar disorder: an update. Abstract presented at: 54th Annual AACAP Meeting; October, 2007; Boston, MA.

DelBello M, et al. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. *Am J Psychiatry*. 2007;164(4):582-590.

DelBello M, et al. Magnetic resonance imaging analysis of amygdala and other subcortical brain regions in adolescents with bipolar disorder. *Bipolar Disord*. 2004;6(1):43-52.

DelBello M, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. *J Am Acad Child Adolesc Psychiatry*. 2006;45(3):305-313.

DelBello M, et al. MRI analysis of the cerebellum in bipolar disorder: a pilot study. *Neuropsychopharmacology*. 1999;21(1):63-68.

Delbello M, et al. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. *Neuropsychopharmacol*. 2006;31:1264-1273.

DelBello M, Kowatch R. Pharmacological interventions for bipolar youth: developmental considerations. *Dev Psychopathol*. 2006;18(4):1231-1246.

Dixon L, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. *J Nerv Ment Dis*. 1999;87(8):496-502.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *JAMA*. 2001;285(19):2486-2497.

Fagiolini A, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. *Am J Psychiatry*. 2003;160(1):112-117.

Fagiolini A, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. *Bipolar Disord*. 2005;7(5):424-430.

Friedman S, et al. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. *Biol Psychiatry*. 2004;56(5):340-348.

Gareri P, et al. Conventional and atypical antipsychotics in the elderly: a review. *Clin Drug Invest*. 2003;23(5):287-322.

Geddes J, et al. Bipolar disorder—services need to catch up with rapidly developing evidence base. *BMJ*. 2006;332:32-33.

Geller B, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. *J Am Acad Child Adolesc Psychiatry*. 1998;37(2):171-178.

Goff D, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr Res*. 2005;80(1):45-53.

Goldberg J, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. *Am J Psychiatry*. 2007;164(9):1348-1355.

Goldberg J, et al. A history of substance abuse complicates remission from acute mania in bipolar disorder. *J Clin Psychiatry*. 1999;60:733-740.

Goldberg J, et al. What constitutes evidence-based pharmacotherapy for bipolar disorder? Part 1: First-line treatments. *J Clin Psychiatry*. 2007;68(12):1982-1983.

Goldberg J. *J Clin Psychiatry*. In press.

Goldstein J, et al. Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. *Eur Neuropsychopharmacol*. 2007;17(S4):S401.

Gonzalez J, et al. Treatment characteristics and illness burden among European Americans, African Americans, and Latinos in the first 2,000 patients of the systematic treatment enhancement program for bipolar disorder. *Psychopharmacol Bull*. 2007;40(1):31-46.

Goodwin F, Jamison K. *Manic Depressive Illness*. Oxford University Press; New York, NY: 2007.

Graves R, et al. Diagnosing bipolar disorder in trauma exposed primary care patients. *Bipolar Disord*. 2007;9(4):318-323.

Grundy S, et al. Diagnosis and management of the metabolic syndrome. *Circulation*. 2005;112:285-290.

Hasler G, et al. Toward constructing an endophenotype strategy for bipolar disorders. *Biol Psychiatry*. 2006;60(2):93-105.

Hennekens C, et al. Schizophrenia and increased risks of cardiovascular disease. *Am Heart J*. 2005;150(6):1115-1121.

Herran A, et al. Determinants of smoking behaviour in outpatients with schizophrenia. *Schizophr Res*. 2000;41(2):373-381.

Hirschfeld R, et al. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. *J Clin Psychiatry*. 2003;64(2):161-174.

Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder. *CNS Drugs*. 2007;21(1):1-11.

Keck P, et al. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. *J Clin Psychiatry*. 2006;67(Suppl 1):8-15.

Kilbourne A, et al. Burden of general medical conditions among individuals with bipolar disorder. *Bipolar Disord*. 2004;6(5):368-373.

Koro C, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. *Arch Gen Psychiatry*. 2002;59(11):1021-1026.

Leverich G, et al. The poor prognosis of childhood-onset bipolar disorder. *J Pediatr*. 2007;150(5):485-490.

Lish J, et al. The national depressive and manic-depressive association (DMDA) survey of bipolar members. *J Affect Disord*. 1994;31(4):281-294.

McElroy S, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. *J Clin Psychiatry*. 2002;63(3):207-213.

McElroy S, et al. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). 3rd Biennial Conference of the International Society for Bipolar Disorders; January 2008; New Delhi, India.

McEwen B. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. *Ann NY Acad Sci*. 2004;1032:1-7.

McGuffin P. The genetics of bipolar disorder and its relationship with unipolar depression. *Actas Esp Psiquiatr*. 2008;36(Suppl 1):48-50.

McIntyre R, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. *Can J Psychiatry*. 2006;51(5):274-280.

McIntyre R, et al. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. *J Clin Psychiatry*. 2007;68(9):1352-1357.

Mental Health America. Available at: <http://www.mentalhealthamerica.net/go/information/get-info/bipolar-disorder/bipolar-disorder-and-african-americans>. Accessed April 2008.

- Merikangas K, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2007;64:543-552.
- Michael N, et al. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. *Psychopharmacol*. 2003;168(3):344-346.
- Moore C, et al. Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. *Bipolar Disord*. 2000;2(3 pt 2):207-216.
- Moore G, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. *Am J Psychiatry*. 1999;156(12):1902-1908.
- Moreno C, et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. *Arch Gen Psychiatry*. 2007;64(9):1032-1039.
- Nasrallah H. Evaluating the evidence: clinical antipsychotic trials of intervention effectiveness (CATIE) and beyond. *J Clin Psychiatry*. 2007;68(S1):3-11.
- Nasrallah H, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. *Schizophr Res*. 2006;86(1-3):15-22.
- Newcomer J, Hennekens C. Severe mental illness and risk of cardiovascular disease. *JAMA*. 2007;298(15):1794-1796.
- Nierenberg A, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or resperidone. *Am J Psychiatry*. 2006;163:210-216.
- O'Brien S, et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. *J Affect Disord*. 2006;90(2-3):263-267.
- Olfson M, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. *Arch Gen Psychiatry*. 2006;63(6):679-685.
- Osby U, et al. Excess mortality in bipolar and unipolar disorder in Sweden. *Arch Gen Psychiatry*. 2001;58(9):844-850.
- Patel N, et al. Open-label lithium for the treatment of adolescents with bipolar depression. *J Am Acad Child Adolesc Psychiatry*. 2006;45(3):289-297.
- Patel N, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. *J Child Adolesc Psychopharmacol*. 2007;17(3):303-311.
- Post R. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. *J Psychiatr Res*. 2007;41(12):979-990.
- Preskorn S. The slippery slide. *J Pract Psychiatry Behav Health*. 1999;5:50-55.
- Regenold W, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. *J Affect Disord*. 2002;70(1):19-26.
- Ruzickova M, et al. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. *Can J Psychiatry*. 2003;48(7):458-461.
- Sachs G. Bipolar disorder clinical synthesis: where does the evidence lead? *FOCUS*. 2007;5(1):3-13.
- Sachs G, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. *N Eng J Med*. 2007;356(11):1711-1722.
- Salloum I, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism. *Arch Gen Psychiatry*. 2005;62:37-45.
- Schloesser R, et al. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. *Neuropsychopharmacology*. 2008;33(1):110-133.
- Schneck C, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. *Am J Psychiatry*. 2008;165:370-377.
- Stork C, Renshaw P. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. *Molecular Psychiatry*. 2005;10(10):900-919.

- Strakowski S, et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. *Am J Psychiatry*. 2002;159(11):1841-1847.
- Strakowski S, et al. Abnormal fMRI brain activation in euthymic bipolar disorder patients during a counting Stroop interference task. *Am J Psychiatry*. 2005;162(9):1697-1705.
- Strakowski S, et al. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. *Arch Gen Psychiatry*. 1999;56(3):254-260.
- Strakowski S, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. *Arch Gen Psychiatry*. 2007;64(1):57-64.
- Strakowski S, et al. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. *Molecular Psychiatry*. 2005;10(1):105-116.
- Strakowski S, et al. A preliminary fMRI study of sustained attention in euthymic, unmedicated bipolar disorder. *Neuropsychopharmacology*. 2004;29(9):1734-1740.
- Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. *J Clin Psychiatry*. 2006;67(7):1034-1041.
- Thase M, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression. *J Clin Psychopharmacol*. 2006;26(6):600-609.
- The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007;447(7):661-683.
- Tohen M, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. *Am J Psychiatry*. 2007;164(10):1547-1556.
- Tohen M, et al. Four-year follow-up of twenty-four first-episode manic patients. *J Affect Disord*. 1990;19:79-86.
- Truman C, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the systematic treatment enhancement program for bipolar disorder (STEP-BD). *J Clin Psychiatry*. 2007;68(10):1472-1479.
- Ucok A, et al. Cigarette smoking among patients with schizophrenia and bipolar disorders. *Psychiatry Clin Neurosci*. 2004;58(4):434-437.
- Van der Loos M, et al. *J Clin Psychiatry*. In Press.
- Versavel M, et al. Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder. *Neuropsychopharmacol*. 2005;30(S1):S122, Abstract 116.
- Wagner K, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. *Am J Psychiatry*. 2006;163:1179-1186.
- Weiden P, et al. Translating the psychopharmacology of antipsychotics to individualized treatment of severe mental illness: a roadmap. *J Clin Psychiatry*. 2007;68(7):5-46.
- Weiss R, et al. Medication compliance among patients with bipolar disorder and substance use disorder. *J Clin Psychiatry*. 1998;59:172-174.
- Weiss R, et al. Does recovery from substance use disorder matter in patients with bipolar disorder? *J Clin Psychiatry*. 2005;66:730-735.
- Wilson C, et al. Cytokines and cognition—the case for a head-to-toe inflammatory paradigm. *J Amer Geriatrics Soc*. 2002;50(12):2041-2056.
- Winsberg M, et al. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. *Biol Psychiatry*. 2000;47(6):475-481.
- Young A, et al. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and lithium in adults with bipolar depression (EMBOLDEN I). 3rd Biennial Conference of the International Society for Bipolar Disorders; January 2008; New Delhi, India.